Login to Your Account



Abuse Risk Dominates Talks

FDA Panel Gives Zogenix's Pain Drug a Thumbs Down

By Randy Osborne
Staff Writer

Monday, December 10, 2012
Grisly and dramatic testimony jarred the public-comment segment of the FDA advisory panel on Zohydro for chronic pain, as parents of opioid casualties begged committee members to turn thumbs down on Zogenix Inc.'s extended-release hydrocodone.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription